Barbara Pavik is the founder of Asceneuron. Asceneuron has raised $100M in total funding. Latest round: Series C. Based in Lausanne, Vaud, CH.
Barbara Angehrn Pavik is the Chief Executive Officer of Asceneuron, a clinical-stage biotech company developing orally bioavailable therapeutics for neurodegenerative disorders like Alzheimer's disease. She successfully secured a $100 million oversubscribed Series C financing round in July 2024 to advance Asceneuron's lead asset ASN51 into Phase 2 clinical development. As of 2026, she has transitioned to serve as CEO of Numab Therapeutics, having previously held the CEO role at Asceneuron.
Full founder directory · Investor directory · Company funding database · Fundraising library